TrialJournal for immunotherapy of cancer2025

Pharmacokinetics and safety of subcutaneous nivolumab: results from the phase I/II CheckMate 8KX study.

Sara Lonardi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.